Tool 9: Report on the Experiences and Learnings from the first ERN-Industry pilots supported by Together4RD

Published by

European Reference NetworkIndustry collaborationRare DiseaseResearch and Drug Development

In 2024, the Together4RD Secretariat interviewed key individuals from both Industry and ERNs, about their experiences in launching the first 3 ERN-Industry pilot projects. These interviews were intended to better understand the respective experiences of conceptualizing and initiating these pilots – from who came up with the original idea, to how the project proposals have taken shape, covering activities up to the launch phase (approximately). The main insights are summarized in this Report

View this resource Bookmark this resource

Tool 8: Summary of areas or activities for potential ERN and Industry collaboration

Published by

European Reference NetworkIndustry collaborationRare DiseaseResearch and Drug Development

Stakeholders sometimes struggle to consider the range of activities on which ERNs and Industry could collaborate, besides the more traditional engagement around clinical trials, or more recently, partnering with multiple companies through the European Federation of Pharmaceutical Industries and Associations (EFPIA), in a large project via the Innovative Medicines Initiative, for instance. This resource builds upon material prepared for the comprehensive Together4RD Position Statement, to present a table listing a broad range of potential projects and activities which might be well-suited to ERN and Industry collaboration.

View this resource Bookmark this resource

EATRIS Matchmaking for lab services

Published by n/a

core facilityEATRISIndustry collaborationtechnology platforms

EATRIS facilitates academic collaborations with industry. It identifIes scientific & medical expertise and find the capacity to provide access to the latest technologies and core facilities from within our technology platforms.It serves as a single point of contact, provides (legal) support and acts as a negotiator to facilitate project initiation and monitor project execution when needed. Its infrastructure consists of 115+ biomedical research institutes in 14 EU countries.

View this resource Bookmark this resource